michael andreeff (19 Ergebnisse)

Hardcover. Zustand: Very Good. Very good hardcover. No DJ. Text is clean and unmarked. Covers show very minor shelf wear. Bindings tight, hinges strong. Previous owners business card applied to inside front cover.; 100% Satisfaction Guaranteed! Ships same or next business day!

Broschiert. Zustand: Gut. XV, 182 S. Das hier angebotene Buch stammt aus einer teilaufgelösten wissenschaftlichen Bibliothek und trägt die entsprechenden Kennzeichnungen (Rückenschild, Instituts-Stempel.). Schnitt und Einband sind etwas staubschmutzig; der Buchzustand ist ansonsten ordentlich und dem Alter entsprechend gut. Sprache: Deutsch Gewicht in Gramm: 400.

Zustand: Near Fine. NY 1986. Annals of New York Academy of Science, Vol. 468. Octavo, original printed hardcover. A few institution stamps, but no spine numbers and no pocket. Near Fine.

Hardcover. Zustand: Very Good. Concise Manual of Hematology and Oncology This book is in very good condition and will be shipped within 24 hours of ordering. The cover may have some limited signs of wear but the pages are clean, intact and the spine remains undamaged. This book has clearly been well maintained and looked after thus far. Money back guarantee if you are not satisfied. See all our books here, order more than 1 book and get discounted shipping. .

VIII, 141 Seiten. 49 graphische Darstellungen und 56 Tabellen. Großoktav (24x16 cm) Orig.Karton. ** Gutes, sauberes Exemplar. Mit persönlicher Widmung des Autors J. Schumann.

Hardcover. Zustand: Very Good. Shipped within 24 hours from our UK warehouse. Clean, undamaged book with no damage to pages and minimal wear to the cover. Spine still tight, in very good condition. Remember if you are not happy, you are covered by our 100% money back guarantee.

Zustand: Very Good. Very Good++; Hardcover; Close to new condition; Covers are still glossy with "straight" edge-corners; Unblemished textblock edges; The endpapers and all text pages are bright and unmarked; Binding is tight with a straight spine; This book will be stored and delivered in a sturdy cardboard box with foam padding; Medium Format (8.5" - 9.75" tall); Blue, purple, and orange covers with title in white lettering; 2014, Springer-Verlag Publishing; 826 pages; "Targeted Therapy of Acute Myeloid Leukemia (Current Cancer Research)," by Michael Andreeff.

Zustand: New.

Gebunden. Zustand: New.

Taschenbuch. Zustand: Neu. Targeted Therapy of Acute Myeloid Leukemia | Michael Andreeff | Taschenbuch | xix | Englisch | 2016 | Springer US | EAN 9781493939893 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Buch. Zustand: Neu. Neuware -This book provides an unprecedented overview of 'Targeted Therapies' for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make 'leukemia history' in the near future.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 848 pp. Englisch.

Taschenbuch. Zustand: Neu. Neuware -This book provides an unprecedented overview of 'Targeted Therapies' for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make 'leukemia history' in the near future.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 848 pp. Englisch.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides an unprecedented overview of 'Targeted Therapies' for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make 'leukemia history' in the near future.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides an unprecedented overview of 'Targeted Therapies' for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make 'leukemia history' in the near future.

Paperback. Zustand: Brand New. reprint edition. 845 pages. 9.25x6.10x1.93 inches. In Stock.

Hardcover. Zustand: Brand New. 1st edition. 826 pages. 9.25x6.25x2.00 inches. In Stock.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - How Do We Treat Hematology and Oncology have seen rapid progress and advances during recent years. Increased knowledge of tumor biology, epidemiology, molecular genetics, growth reg- lation, and cellular functions has led to novel therapeutic paradigms. Targeted trea- ment approaches, antibodies, immunotherapy, and other new techniques complement classic chemotherapy, radiotherapy, and surgery. Patients are increasingly well educated as web-based information on diagnostic and therapeutic options as well as quality ma- agement and tumor outcome data are readily available. In this dynamic and fast-paced environment, it is of central importance to base clinical decisions and medical practice on the best available evidence. Continuous quality ma- agement, with clinical process documentation, standardization, and evaluation, leads to improved patient care and long-term outcomes. For these reasons, we have started to systematically capture and evaluate data on diagnosis, treatment, and outcomes of p- tients with solid tumors and hematological neoplasms at the Freiburg University Med- cal Center. We have developed standard operating procedures, clinical pathways, and diagnostic and therapeutic processes, following the principles of 'Good Clinical Pra- tice.' Tese processes (e.g., detailed protocols for chemotherapy application, treatment fowcharts, clinical pathways) are continuously tested and validated in clinical practice.

Zustand: New.

Bibliothekseinband. Zustand: Gut. XV, 182 S. : 97 Ill. u. graph. Darst., , 24 cm Beiträge teilw. dt., teilw. engl. aus einer wissenschaftlichen Bibliothek Sprache: Deutsch Gewicht in Gramm: 550.